Hepatitis B Virus Polymerase Blocks Pattern Recognition Receptor Signaling via Interaction with DDX3: Implications for Immune Evasion

Haifeng Wang, Wang-Shick Ryu*
Department of Biochemistry, Yonsei University, Seoul, Korea

Abstract

Viral infection leads to induction of pattern-recognition receptor signaling, which leads to interferon regulatory factor (IRF) activation and ultimately interferon (IFN) production. To establish infection, many viruses have strategies to evade the innate immunity. For the hepatitis B virus (HBV), which causes chronic infection in the liver, the evasion strategy remains uncertain. We now show that HBV polymerase (Pol) blocks IRF signaling, indicating that HBV Pol is the viral molecule that effectively counters acts host innate immune response. In particular, HBV Pol inhibits TANK-binding kinase 1 (TBK1)/1xB kinase-e (IKKɛ), the effector kinases of IRF signaling. Intriguingly, HBV Pol inhibits TBK1/IKKɛ activity by disrupting the interaction between IKKɛ and DDX3 DEAD box RNA helicase, which was recently shown to augment TBK1/IKKɛ activity. This unexpected role of HBV Pol may explain how HBV evades innate immune response in the early phase of the infection. A therapeutic implication of this work is that a strategy to interfere with the HBV Pol-DDX3 interaction might lead to the resolution of life-long persistent infection.

Introduction

Hepatitis B virus (HBV) is the prototypic member of the hepadnavirus family and a major cause of liver diseases. An estimated 400 million people are persistently infected with HBV worldwide. A significant subset of these HBV carriers progresses to severe liver disease, such as hepatocellular carcinoma, which may cause up to one million deaths per year. Interferon and nucleoside analogs such as lamivudine and adefovir are used to treat chronic hepatitis B patients but have limited utility due to the adverse effect and the emergence of drug-resistant variants, respectively [1]. Thus, there is a clear medical need for new therapeutic strategies.

Viral infection leads to the initiation of antiviral innate immune responses resulting in the expression of type I interferons (IFNs), IFNα and IFNβ, and pro-inflammatory cytokines [2]. Recently, the cellular mechanisms used to detect viruses and elicit production of IFNs and pro-inflammatory cytokines have been described in detail. It is now well-established that viruses, similar to bacteria and fungi, are initially recognized by host pattern-recognition receptors (PRRs) [2,3]. Viral nucleic acids (both RNA and DNA) are the most important pathogen-associated molecular patterns (PAMPs) recognized by PRRs [3]. Two families of PRRs have been defined. The first is a subfamily of Toll-like receptors (TLRs) that include TLR3, TLR7, TLR8, and TLR9, which are mainly expressed in the endosomes of some cell types, especially plasmacytoid dendritic cells. Recognition by TLRs of viral PAMPs initiates TLR-mediated signaling pathways that culminate in the activation of transcription factors NFκB, IRF3, and IRF7. Specifically, TLRs recruit signaling adaptors, including TIR-domain-containing adaptor protein inducing IFNβ (TRIF). This activates TANK-binding kinase 1 (TBK1)/1xB kinase-e (IKKɛ) to phosphorylate and activate the transcription factors IFN-regulatory factors (IFR) 3 and 7 [2,4]. The second family of PRRs comprises the retinoic-acid inducible gene 1 (RIG-I)-like receptors (RLRs), including RIG-I and melanoma differentiation-associated gene 5 (MDA-5) [3]. Similar to TLRs, the recognition of viral nucleic acids by RLRs leads to a cascade of signaling events that result in activation of NF-κB, IRF3, and IRF7. Specifically, RLRs recruit the signaling adaptor protein IFNβ-promoter stimulator 1 (IPS-1, also known as MAVS, VISA, or Cardif), activating the downstream TBK1/IKKɛ kinases, which then phosphorylate and activate IRF3 and IRF7 [2]. The capacity of both signaling pathways to restrict viral replication is consistent with their downstream convergence at the TBK1/IKKɛ kinases responsible for activation of IRF-3.

As stated above, viral infection leads to activation of cellular signaling such as IRF signaling, which culminates in IFN production. Infection by HBV appeared to be an exception. In an acute HBV-infected chimpanzee model, Chisari and colleagues have reported that HBV fails to induce transcription of any cellular genes that relate to the entry and expansion of the virus, implicating the lack of innate immune response upon HBV infection [5,6]. By contrast to the earlier report, evidence was accumulating, which indicated that the innate immune system is, in fact, able to sense HBV infection. An early induction of innate

Citation: Wang H, Ryu W-S (2010) Hepatitis B Virus Polymerase Blocks Pattern Recognition Receptor Signaling via Interaction with DDX3: Implications for Immune Evasion. PLoS Pathog 6(7): e1000986. doi:10.1371/journal.ppat.1000986

Editor: Jing-hsiung James Ou, University of Southern California, United States of America

Received January 21, 2010; Accepted June 4, 2010; Published July 15, 2010

Copyright: © 2010 Wang, Ryu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by a grant of the Korean Health Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A100217). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: wsryu@yonsei.ac.kr
Viral infection is sensed by the host innate immune system, which acts to limit viral infection by inducing antiviral cytokines such as the interferons. To establish infection, many viruses have strategies to evade the innate immunity. For the hepatitis B virus (HBV), which causes chronic infection in the liver, the evasion strategy remains mysterious. An earlier study using the chimpanzee as a model suggested that the host innate immune system failed to detect HBV. As a result, it was dubbed “stealth virus”. In contrast, subsequent studies performed in vitro have suggested that HBV is, in fact, detected by the innate immune system but can effectively counteract this response. Whether HBV is detected by the innate immune system remains controversial; however, it is widely accepted that, regardless of detection, HBV effectively inhibits the host innate immune response early in infection through an unknown mechanism. The data presented here indicate that HBV Pol (polymerase or reverse transcriptase) blocks the innate immune response. This unexpected role of HBV Pol may explain why HBV appears to act as a “stealth virus” in the early phase of the infection.

The poly I:C is recognized by TLR3 in endosomes by adding it to the cell medium, whereas it is recognized by MDA5 when it is delivered to the cytoplasm by transfection via lipofectin [16,17]. These results suggested that HBV Pol derived from the HBV replicon – wild-type or X-null, or C-null replicon – decreased IFN production, implicating the physiological relevance of the findings in the viral life cycle. Intriguingly, IFN promoter activity induced by HBV P-null replicon was significantly higher than what was achieved by poly I:C (Fig. 1C). The implication is that some yet-to-be-known viral PAMPS derived from HBV P-null replicon could contribute to the augmented IFN promoter activity (see Discussion).

HBV Pol inhibits IFNβ promoter triggered by RIG-I/MDA5 as well as TLR3 receptor signaling

To examine whether HBV Pol could suppress diverse PAMP-mediated signaling, poly I:C was given to cells by two distinct routes: (i) addition to medium, and (ii) transfection via lipofectin. The poly I:C is recognized by TLR3 in endosomes by adding it to the cell medium, whereas it is recognized by MDA5 when it is delivered to the cytoplasm by transfection via lipofectin [16,17]. Cells were transfected with incremental dose of the HBV Pol and TLR3 expression constructs along with the reporter construct. Following treatment with poly I:C in the medium, the reporter assay result showed a dose-related decrease of IFN promoter activity by HBV Pol expression, corroborating the above conclusions (Fig. 2A). Likewise, when poly I:C was given by lipofectin transfection, IFN promoter activity was similarly decreased by HBV Pol (Fig. 2B).
Next, innate immune response was triggered by Sendai virus (SenV), a potent stimulus of the RIG-I pathway [17,18]. Cells were transfected with the HBV Pol expression construct and the IFN-luciferase construct. Two days after transfection, cells were treated with 100 HA U/mL of SenV for 6 h before harvest. The data indicated that HBV Pol diminished IFN promoter activity in

Figure 1. HBV Pol inhibits dsRNA-induced IFNβ promoter activation. (A) HepG2 cells in 6-well plate were transfected with HBV Pol, core, or HBx, and the YMHD mutant of HBV Pol expression constructs together with an IFNβ luciferase reporter and TLR3 expression constructs. Cells were stimulated with 25 μg/mL poly I:C directly added to culture medium for 8 h. Data are expressed as the mean fold induction ± s.d. relative to mock-treated cells. The results are representative of at least four independent experiments. (B) An experiment was performed as shown in panel (A), with an exception of transfecting three viral surface antigen expression constructs: L-HBsAg (L), and M-HBsAg (M), and S-HBsAg (S). (C) HepG2 cells were transfected with empty vector, WT, X-null, C-null, and P-null HBV replicon together with the IFNβ reporter construct. Student’s t test was used for statistical analysis, and a P value of <0.05 was considered statistically significant. Poly I:C treatment was done as in panel (A). (See also Fig. S1).

doi:10.1371/journal.ppat.1000986.g001
Overall, the data presented suggest that HBV Pol suppresses RIG-I mediated IFN production as well as TLR3-mediated IFN production. To substantiate the above findings, we wanted to eliminate a possibility that the reduction of the IFN promoter activities by HBV Pol is ascribed to the over-expression of HBV Pol. To assess whether the HBV Pol we expressed ranges the physiological level, we sought to show that the amount of viral DNAs synthesized via complementation by the HBV Pol in the HBV P-null replicon transfected cells is comparable to that of WT HBV replicon transfected cells. To this end, HepG2 cells were transfected with the same four increasing amount of the HBV Pol expression construct as above to complement the P-null construct (i.e., P-) for the viral genome replication. Viral DNAs extracted from cytoplasmic capsids were measured by Southern blot analysis (Fig. S2). The data showed that the amount of viral DNA synthesized by complementation was less than that of WT HBV (Fig. S2, lane 1 versus lanes 3 to 5), suggesting that the HBV Pol expressed in the Fig. 2A to Fig. 2C was not exceeding physiological level. In addition, by using HepG2.2.15 cell line that stably expresses viral proteins and support HBV replication [19], we consistently found that IFN promoter activity induced upon SenV (Sendai virus) infection was pronouncedly diminished in HepG2.2.15 cells (Fig. 2D), validating the impact of HBV Pol in a more physiological setting.

HBV Pol abrogates nuclear translocation and phosphorylation of IRF3

Phosphorylation and nuclear translocation of IRF3 represent hallmarks of antiviral innate immunity. To examine whether HBV Pol inhibits the phosphorylation of IRF3, cells were transfected with TLR3 and HBV Pol construct as indicated. Eight hours before harvest, cells were then treated with poly I:C. Endogenous IRF3 and its phosphorylated counterparts were detected by Western blot analysis with anti-IRF3 and anti-phosphorylated IRF3 (Ser396) antibodies, respectively (Fig. 3A). As anticipated, Western blot analysis indicated that the higher molecular weight bands of endogenous IRF3, which represent phosphorylated IRF3, appeared when cells were treated with poly I:C (Fig. 3A, lane 2). However, the phosphorylated IRF3 was undetectable.
following HBV Pol expression (Fig. 3A, lane 3), suggesting that HBV Pol inhibits phosphorylation of IRF3. (see below for the explanation for lane 4).

Nuclear translocation of IRF3 was examined by fluorescence microscopy. Cells were transfected with the IRF3-GFP fusion protein construct to monitor IRF3 nuclear localization (Fig. 3B). Cells were also transfected with HBV Pol and TLR3 constructs and then treated with poly I.C. As previously demonstrated [20], IRF3-GFP predominantly found in the cytoplasm was induced to undergo nuclear localization only when cells were treated with poly I.C (Fig. 3B, panel a versus panel b). By contrast, IRF3-GFP remained localized in cytoplasm when cells were transfected by HBV Pol and treated with poly I.C (Fig. 3B, panel c), suggesting that HBV Pol prevents the nuclear translocation of IRF3-GFP. Overall, these data are consistent with the conclusion that HBV Pol inhibits the IRF signaling. (see below for the explanation for panel d).
HBV Pol suppressed both TRIF and RIG-I triggered IRF signaling

To further elucidate the specific mechanism by which viral HBV Pol interferes with IRF signaling, the impact of HBV Pol on the signaling pathway leading to IRF activation was investigated. To trigger RIG-I mediated IRF3 signaling, RIG-I was over-expressed. On the other hand, TRIF is an adaptor for the TLR3 receptor and mimics TLR3 signaling when over-expressed. To trigger TLR3-mediated IRF3-signaling, TRIF over-expression was employed. Cells were transfected with the IRF3 reporter construct and an incremental dose of HBV Pol expression construct, along with either RIG-I or TRIF (Fig. 4A and Fig. 4B). The data indicated that the luciferase activity was decreased by HBV Pol in a dose-dependent manner (Fig. 4A and Fig. 4B). Thus, we concluded that HBV Pol inhibited both TLR3-mediated and RIG-I-mediated IRF3 signaling.

HBV Pol suppressed TBK1/IKKe triggered IRF 3/7 signaling

The TBK1/IKKe complex represents the effector protein kinase of IRF signaling, phosphorylating IRF3/7, when activated by appropriate recruitment of IPS/MAVS or TRIF (Fig. 5A). The results shown above indicated that both TLR3- or RIG-I-mediated IRF signaling was inhibited by HBV Pol, and the phosphorylation of IRF3/7 was blocked by HBV Pol. Thus, it is conceivable that HBV Pol inhibits TBK1/IKKe activity. To gain further insight into the mechanism by which HBV Pol interferes with TLR3-mediated and RIG-I-mediated IRF signaling, we determined if TBK1 or IKKe triggered IRF signaling could also be blocked by HBV Pol. Cells were transfected with either TBK1 or IKKe, and IRF3 reporter construct along with incremental doses of the HBV Pol construct. Results indicated that IRF3 signaling was triggered either by TBK1 or IKKe over-expression and was blocked by HBV Pol in a dose-dependent manner (Fig. 5B and 5C). Essentially identical data were obtained with an IRF7 reporter assay performed in parallel (data not shown). Thus, the data suggested that HBV Pol exerts its inhibitory effect on TBK1/IKKe or another downstream point in this pathway. An ISRE reporter assay was then carried out, which indicated that HBV Pol inhibited IKKe-triggered ISRE activation, but not IRF3-triggered ISRE activation (Fig. 5D and 5E). These results pointed to TBK1/IKKe as the molecular target of HBV Pol for the inhibition of IRF signaling.

HBV Pol inhibits TBK1/IKKe activity by disrupting IKKe-DDX3 interaction

Next, we examined whether HBV Pol inhibits TBK1/IKKe activity directly or indirectly. Recently, two independent groups demonstrated that DDX3 enhanced TBK1/IKKe activity via its interaction with TBK1 or IKKe [9,10]. Additionally, we have shown that DDX3 binds to HBV Pol [11]. Thus, we hypothesized that HBV Pol would inhibit TBK1/IKKe activity via interaction with DDX3. One prediction of the hypothesis is that over-expression of DDX3 would restore IRF signaling that has been inhibited by HBV Pol. Previous studies were limited to HEK293 and RAW264.7 macrophages; therefore, we confirmed the importance of DDX3 for the activation of IRF signaling in HepG2 cells following downregulation of DDX3 (Fig. S3A and Fig. S3B). To determine if DDX3 could restore IRF3 signaling suppressed by HBV Pol, cells were transfected by either TBK1 or IKKe constructs along with a maximal level of HBV Pol to obtain the highest level of IRF signaling inhibition. Cells were also cotransfected with increasing doses of the DDX3 construct to determine if DDX3 could restore the diminished IRF signaling. The luciferase data revealed that the ectopic expression of DDX3 rescued the IRF signaling in a dose-dependent manner (Fig. 6A and 6B), indicating that DDX3 antagonizes the inhibitory effect of HBV Pol on IRF signaling. Consistently, ectopic expression of DDX3 also rescued the phosphorylation and nuclear translocation of IRF3 (Fig. 5A, lane 4; Fig. 5B, panel d).

Given the functional interaction between HBV Pol and DDX3 [11], it is possible that HBV Pol disrupts the IKKe-DDX3 interaction. To assess this possibility, a co-immunoprecipitation (co-IP) following transfection of Flag-IKKe, HA-DDX3, and HBV Pol expression constructs was performed (Fig. 6C). Similar to previous reports [9], an interaction between IKKe and DDX3 was observed (Fig. 6C, lane 3). Importantly, when the HBV Pol construct was cotransfected, the IKKe-DDX3 interaction was significantly diminished, consistent with an interpretation that HBV Pol disrupts the IKKe-DDX3 interaction (Fig. 6C, lane 4). It was also noted that DDX3 level was enhanced and a higher molecular weight form of DDX3 was evident when IKKe was

Figure 4. HBV Pol inhibits both RIG-I- and TRIF-induced IRF3 activation. HepG2 cells were cotransfected with increasing doses of the HBV Pol expression construct to determine the effect of HBV Pol on IRF3 signaling. To monitor IRF3 activation, cells were transfected with IRF3-GAL4 expression plasmid together with the GAL4-dependent pFR luciferase reporter construct. Note that 5-fold less amount of HBV Pol construct was used, because 24-well plate, instead of 6-well, was used. To induce IRF3 signaling, RIG-I (A) or TRIF (B) expression constructs were transfected. Data are expressed as the mean fold induction ± s. d. relative to control levels. The results are representative of at least two independent experiments, each performed in triplicate.
doi:10.1371/journal.ppat.1000986.g004
ectopically expressed, which might represent a phosphorylated form (Fig. 6C, lanes 3 and 4); intriguingly, the similar changes of DDX3 were also observed in the previous report [9]. It is conceivable that the phosphorylation of DDX3 by IKKe stabilizes DDX3. Based on the antagonistic activity of DDX3 on the inhibitory effect of HBV Pol on IRF signaling and the disruption of IKKe-DDX3 interaction by HBV Pol, we concluded that HBV Pol suppresses IRF signaling by disrupting the IKKe-DDX3 interaction.

Discussion

HBV, that has been dubbed a “stealth virus”, efficiently evades antiviral innate immune responses early in infection [6]. However, the underlying immune evasion mechanism remained enigmatic. The data presented here revealed that HBV evades host immune response via the inhibition of pattern recognition receptor signaling by one of the viral proteins. Results presented here clearly show that HBV Pol is the viral protein that blocks the TLR3-and RIG-I-induced pattern recognition receptor signaling in a physiologically relevant setting (Fig. 2). Further, evidence suggests that HBV Pol suppresses IRF signaling by inhibiting TBK1/IKKe activity, the effector protein kinase of IRF3/7 signaling (Fig. 3). Importantly, we also demonstrated that HBV Pol inhibits TBK1/IKKe activity by disrupting the interaction between IKKe and DDX3 (Fig. 6C). Overall, besides its inherent catalytic role in viral reverse transcription, our results here confer a novel immune-regulatory role to HBV Pol.

Recent evidence obtained in cultured cells showed that HBV is capable of inducing innate host response [8,21]. However, it remained to be learned how HBV abrogates innate immune response. The data presented here indicate that HBV Pol blocks...
both TLR-mediated and RIG-I-mediated IRF3 signaling (Fig. 1 and Fig. 2). Importantly, two experiments presented here supported the physiological relevance of the impact of HBV Pol on innate immune response. First, the data in Fig. 1C showed that the inhibition of IRF signaling by HBV Pol is physiologically relevant, since the inhibitory effect by HBV Pol was observed under the condition, where the physiological level of viral proteins was attained by using either wild-type or mutant HBV replicon in HepG2 cells (Fig. 1C). This finding is further strengthened by the evidence that IFN production was only marginally induced upon SenV infection in HepG2.2.15 cell line compared to a parental HepG2 cells (Fig. 2D).

Further, the data shown in Fig. 1C is significant in a few respects. It was not unexpected that the extent of inhibition attained by the X-null and C-null construct was comparable to that by the wild-type replicon (Fig. 1C), since similar level of HBV Pol would be expressed in transient transfection setting, regardless of whether viral genome replication is induced. Secondly, the data clearly ruled out a possibility that either X protein (i.e., HBx) or core protein is related to the inhibition, since IFN production in either X-null or C-null transfected cells was comparable to that of WT transfected cells (Fig. 1C). Thirdly, the cells transfected by the P-null replicon mounted significantly and reproducibly higher IFN production than that by mock DNA, suggesting that a viral molecule derived from the P-null replicon caused augmentation of IFN production, in addition to what has already been induced by poly(I:C) (Fig. 1C). It is tempting to speculate that the viral molecule, perhaps viral RNAs, may represent viral PAMPs that caused enhanced IFN production.

Although the liver is an important site for chronic viral infection, little is known about how innate immune response is initiated in hepatocytes [13,22]. We chosen HepG2 cell for the most experiments, a hepatoma cell line, that supports HBV genome replication in a manner depending on HBx expression [14]. Since TLR3 expression is deficient in HepG2 cells, IFNβ reporter assays were carried out following complementation of TLR3; note that HepG2 cell is proficient in RIG-I mediated signaling, which senses SenV [13]. On the other hand, unlike to most other viruses, the PAMP signature of HBV, which are sensed by pattern recognition receptors such as TLRs or RIG-I, has not been defined [2]. Consequently, our analysis was limited to use of poly I:C or SenV to trigger pattern recognition receptor signaling. However, it should be noted that the utilization of heterologous inducers such as poly I:C or SenV in this work does not invalidate

---

**Figure 6. HBV Pol inhibits TBK1/IKKε via an interaction with DDX3.** (A and B) DDX3 rescued IRF signaling, which was inhibited by HBV Pol. HepG2 cells were transfected with indicated amounts of HBV Pol and DDX3 expression constructs. To induce IRF3 signaling, TBK1 (A) or IKKε (B) expression constructs (100 ng) were transfected. IRF3 activation was monitored as shown in Fig. 4. Data are expressed as the mean fold induction ± s.d. relative to control levels. The results are representative of at least two independent experiments each performed in triplicate. (C) HBV Pol disrupted the interaction between DDX3 and IKKε. HEK 293 cells were transfected with Flag-IKKε, HA-DDX3, and HBV Pol expression constructs. Cell lysates were analyzed by IP with the indicated antibodies to assess the interaction between DDX3 and IKKε. For the detection of the Flag-tagged IKKε, mouse anti-FLAG M2 antibody (Sigma, 1:5,000) was used; anti-HA antibody (Amersham) was used to detect DDX3. The results are representative of three independent experiments.

doi:10.1371/journal.ppat.1000986.g006
our conclusions, since the HBV Pol inhibits TBK1/IKKe kinase, which lies downstream of PAMPs in IRF signaling (Fig. 3A). Nonetheless, natural viral infection, rather than transfection, involving susceptible human hepatocytes, merit further investigation, as recently demonstrated in HCV infection [23].

In terms of the impact of HBV Pol on IFN signaling, three observations are worthy of mentioning. First, our preliminary data indicated that in addition to its inhibitory effect on IRF signaling, HBV Pol inhibits, to a lesser extent, NF-kB signaling, which also contributes to IFNβ production (data not shown). If it holds, it would suggest an intriguing possibility in that HBV Pol blocks IFNβ production by interfering two distinct signaling pathways, leading to IFNβ production. Work is in progress to obtain the mechanistic details. Second, relevantly, abundant detection of HBV Pol in nonencapsidated state has implicated that HBV Pol could contribute to viral pathogenesis or immune evasion [24,25]. Lastly, in fact, HBV Pol has been previously identified as one of viral proteins that confer the resistance to IFN treatment [26,27]. It should be noted, however, that we found its inhibitory role in IFN induction (i.e., IRF signaling), whereas the published work found its inhibitory effect in IFN action (i.e., JAK/Stat signaling).

DEAD-box RNA helicases constitute a large family of proteins that comprises at least 38 members in human genome [28]. DEAD-box RNA helicases exhibit multiple roles in diverse aspects of RNA metabolism such as transcription, pre-mRNA splicing, RNA export, translation, and RNA decay [29]. Not surprisingly, DDX3 has also been implicated in multiple distinct cellular processes as well. First, DDX3 has been reported to act as a transcriptional factor in the nucleus [30]. Secondly, DDX3 was shown to bind to eIF4E, a translation initiation factor with cap-binding properties, effectively suppressing translation [31]. Finally, DDX3 has been implicated in various viral life cycles. For instance, DDX3 was shown to be essential for nuclear export of human immunodeficiency virus-1 (HIV-1) RNA through the Rev/RE pathway [32]. In addition, DDX3 supports viral replication of hepatitis C virus (HCV) genome via its interaction with the HCV core protein [33,34]. In contrast, DDX3 was shown to inhibit HBV genome replication via its interaction with HBV Pol [11]. Besides its roles in RNA metabolism, a novel function relevant to innate immunity was recently reported by two groups [9,10]. Although the augmentation of IRF signaling by DDX3 was found independently by two groups, discrepancies have been noted regarding the specific mechanism for DDX3-mediated IRF3 activation. Specifically, Bowie and colleagues [9] demonstrated that the IKKe-DDX3 interaction is significantly enhanced upon SenV infection with concomitant IRF3 phosphorylation, indicating that DDX3 stimulates the protein kinase activity of IKKe. In contrast, Decker and colleagues [10] concluded that DDX3 acts as a transcriptional factor of the IFNB promoter, which is in agreement with the transcriptional role of DDX3 reported by another study [30,35]. Interestingly, we have demonstrated that HBV Pol disrupts the IKKe-DDX3 interaction (Fig. 6C), which is consistent with the conclusions of Bowie and colleagues [7]. However, in-depth analyses are needed to clarify this mechanistic issue.

Throughout evolution, viruses have developed strategies to evade host immune response [36]. Bowie and colleagues [9] revealed that the vaccinia virus K7 protein interferes with IRF signaling by inhibiting TBK1/IKKe activity via a mechanism involving its interaction with DDX3. Here, we demonstrated that HBV Pol impairs IRF signaling by inhibiting TBK1/IKKe activity via the HBV Pol-DDX3 interaction. Although diverse viral proteins including structural proteins and nonstructural proteins have evolved to evade immune response [36], it is intriguing that viral polymerase, besides its inherent catalytic contribution, has evolved to interfere innate immune response. More importantly, it is interesting that vaccinia virus and HBV, two unrelated viruses, acquired the ability to evade the immune response by subverting DDX3 during evolution.

Administration of TLR ligands was shown to inhibit HBV replication in a transgenic mouse model, implying that pattern recognition receptor signaling could be exploited for the treatment of chronic HBV infections [37]. Subsequent studies corroborated the above findings either by transfection studies using hepatoma cell lines [38] or by using nonparenchymal liver cells from mice [39]. Along this line, we speculate that disruption of the HBV Pol-DDX3 interaction by therapeutic intervention could invoke sustained antiviral immune responses leading to resolution of chronic viral infections. In this regard, structural elucidation of the HBV Pol-DDX3 interaction merits further investigation.

This work was presented at the International Meeting on Molecular Biology of Hepatitis B Viruses, which was held in Tours, France from August 30 to September 3 of 2009 [40] and the result similar to ours will be reported by others [41].

Materials and Methods

Cell culture, transfection

HepG2, HepG2.2.15, and HEK293 cells were grown in Dulbecco’s Modified Eagle’s medium supplemented with 10% fetal bovine serum (GIBCO-BRL) and 10 μg/mL gentamycin at 37°C in 5% CO2 and were passaged every third day. Cells were transfected using polyethylenimine (25 kDa, Aldrich, St. Louis, MO) as described [42]. The amount of plasmid DNA transfected (12 μg per 60-mm plate and 30 μg per 100-mm plate) was kept constant by inclusion of vector DNA, pcDNA3. HEK293 cells were employed for the experiment shown in Fig. 3 and Fig. 6, because of its higher transfection efficiency (>80%) compared to that of HepG2 cells (<10%) (data not shown).

Reagents

Polyinosine-polycytidylic acid (poly I:C) was purchased from Amersham. Sendai virus (SenV) was kindly provided by Prof. Moon-Jung Song (Korea University).

Plasmids

All DNA constructs were generated by overlap extension PCR protocols as previously described [43]. HBV Pol expression construct encoding HBV Pol with three copies of Flag tag at its N-terminus has been previously described [42]. The HBV replicon construct (i.e., WT) and its X-null version has been described previously [14]. The HBV C-null and P-null replicons have been described [42].YMHD mutant of HBV Pol was made by substitution of the aspartic acid residue (i.e., 540D), a constituent of YMDD motif critical for catalysis, to histidine (H), as previously described [44]. Three constructs that were used to express the viral envelope glycoproteins– L-HBsAg, and M-HBsAg, and S-HBsAg, was made by inserting the respective ORFs into pcDNA3 (Invitrogen). The sources of the remaining plasmids are as follows: IRF3-GAL4, IRF7-GAL4, pFR luciferase reporter, IFNβ-luc reporter (Bowie, Trinity College Dublin, Ireland), Tbk1-Flag, IkKe-Flag (Dr. Fitzgerald, University of Massachusetts Medical School, Worcester, MA), Flag-RIG-I (Dr. Fujita, Kyoto University), Flag-TRIF (Akira, Osaka University), HA-TLR3 (InvivoGen), pSRE-Luc reporter (Stratagene), HA-DDX3, AS-DDX3 (K. T. Jeang, N.I.H.), and IRF3-GFP (Garcia-Sastre, Mt. Sinai School of Medicine).

Western blot analysis

Western blot analysis was performed as described [42]. For the detection of the Flag tagged Pol protein, mouse anti-FLAG M2 antibody was used.
antibody (Sigma, 1:5000) was used. Anti-IRF antibody (Invitrogen) and phospho-specific IRF3 (Ser396) antibody (Cell Signaling) were used to detect IRF3 and phosphorylated IRF3, respectively.

**Reporter gene assays**

Promoter induction and transcription factor activation were measured using HepG2 cells seeded onto 24-well or 6-well plates and transfected after 24 h with expression vectors and luciferase reporter gene. For the IRF3/7 assay, an IRF3/7-GAL4 fusion vector was used in combination with the pFR luciferase reporter, as previously described [45].

**Southern blot analysis**

Southern blot analysis was performed as previously described [46]. Briefly, the extracted viral DNA was separated by electrophoresis through a 1.3% agarose gel in a 0.5× Tris-acetate-EDTA buffer and then transferred onto a nylon membrane. The nylon membrane was prehybridized and hybridized with a 32P-labeled full-length HBV DNA probe in a hybridization solution for 16 h at 65°C. Images were obtained using the phosphoimager (BAS-2500; Fujifilm).

**Co-immunoprecipitation**

Immunoprecipitation was performed as described with modifications [47]. Briefly, after transient transfection, the medium was removed and the cells were rinsed twice in cold PBS, incubated for 30 min at 4°C in lysis buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.2 mM PMSF, and 1% NP-40], and collected by scraping. Cell debris was removed through centrifugation at 10,000 × g for 10 min at 4°C. Extracts were pre-cleared with protein G-agarose beads for 1 h at 4°C. The primary antibody was added for 1 h at 4°C, and immunoglobulin G complexes were collected on protein G-agarose beads for 1 h at 4°C. The beads were washed five times with 1 ml of lysis buffer. Protein complexes were recovered by boiling in Laemmli sample buffer and analyzed by SDS-PAGE.

**Confocal imaging**

HEK293 cells were grown on 18-mm coverslips in 12-well plates and transfected with 2.5 µg of total DNA. At 48 h after transfection, cells were fixed with 3.7% formaldehyde. Slides were mounted onto glass slides with ProLong Antifade Kit (Molecular Probes) and examined by confocal microscopy (LSM 510 Meta; Carl Zeiss, Germany).

**Accession numbers**

HBV ayw subtype: V01460 J02203

DDX3: accession NM_001356.3

**References**

1. Zoulim F (2006) Antiviral therapy of chronic hepatitis B. Antiviral Res 71: 206–215.
2. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124: 783–801.
3. Pichlmair A, Reis e Sousa C (2007) Innate recognition of viruses. Immunity 27: 370–383.
4. Honda K, Taniguchi T (2006) IRFs: master regulators of signalling by Toll-like receptors and cytokine-pattern-recognition receptors. Nat Rev Immunol 6: 644–658.
5. Wieland S, Thimme R, Porcell RH, Chisari FV (2004) Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 101: 6669–6674.
6. Wieland SF, Chisari FV (2005) Stealth and cunning: hepatitis B and hepatitis C viruses. J Viral 79: 9369–9380.
7. Fiscarelli P, Valdatta C, Roni C, Massari M, Mori C, et al. (2009) Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58: 974–982.
8. Lucifora J, Durante D, Testoni B, Hauz O, Leverro M, et al. (2010) Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 51: 63–72.
9. Schroder M, Baran M, Bowie AG (2008) Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J 27: 2147–2157.
10. Soulata D, Burckstummer T, Westermayer S, Goncalves A, Bauch A, et al. (2008) The DEAD-box helicase DDX3 is a critical component of the TANK-binding kinase 1-dependent innate immune response. EMBO J 27: 2115–2126.
11. Wang H, Kim S, Ryu WS (2009) DDX3 DEAD-Box RNA helicase inhibits hepatitis B virus reverse transcription by incorporation into nucleocapsids. J Virol 83: 5015–5024.
12. Alexioupolou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732–738.
13. Li K, Chen Z, Kato N, Gale M, Jr., Lemon SM (2005) Distinct poly(C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem 280: 16739–16747.

14. Cha MY, Ryu DK, Jung HS, Chang HE, Ryu WS (2009) Stimulation of hemorrhagic B Virus genome replication by HBx is linked to both nuclear and cytoplasmic HBx expression. J Gen Virol 90: 978–986.

15. Nassal M (2008) Hepatitis B viruses: reverse transcription a different way. Virus Res 134: 233–249.

16. Sato T, Gale M, Jr. (2006) Differential recognition of double-stranded RNA by RIG-I-like receptors in antiviral immunity. J Exp Med 205: 1523–1527.

17. Kato H, Takeuchi O, Sato S, Yoneyma M, Yamamoto M, et al. (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101–105.

18. Yoneyma M, Kikuchi T, Inoue N, Imai K, Tada S, et al. (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5: 730–737.

19. Sells MA, Chen ML, Acs G (1987) Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A 84: 1005–1009.

20. Miyahashi M, Martinez-Sobrido L, Zuo YM, Cardenas WB, Gale M, Jr., et al. (2007) Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol 81: 314–324.

21. Wu J, Meng Z, Jiang M, Pei R, Trippler M, et al. (2009) Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 49: 1132–1140.

22. Preiss S, Thompson A, Chen X, Rodgers S, Markovska V, et al. (2008) Characterization of the innate immune signalling pathways in hepatocyte cell lines. J Viral Hepat 15: 888–900.

23. Wang N, Liang Y, Devaraj S, Wang J, Lemon SM, et al. (2009) Toll-like receptor 3 Mediates Establishment of an Antiviral State Against Hepatitis C Virus in Hepatoma Cells. J Virol.

24. Yao E, Gong Y, Chen N, Tavis JE (2000) The Majority of Duck Hepatitis B Virus Reverse Transcriptase in Cells Is Nonencapsidated and Is Bound to a Hepatitis B Virus-Activated Signaling Pathways Leading to Interferon-Beta Production. J Virol.

25. Cao F, Tavis JE (2004) Detection and characterization of cytoplasmic hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKK and RIG-I. J Gen Virol 91: 1029–1039.

26. Foster GR, Ackrill AM, Goldin RD, Kerr IM, Thomas HC, et al. (1991) Characterization of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA [published erratum appears in Proc Natl Acad Sci U S A 1991 Apr 11:92(8):3632]. Proc Natl Acad Sci U S A 88: 2889–2892.

27. Wu M, Xu Y, Lin S, Zhang X, Xiang L, et al. (2007) Hepatitis B virus polymerase inhibits the interferon-inducible MDA58 promoter by blocking nuclear translocation of Stat1. J Gen Virol 88: 2888–2892.

28. Linder P (2006) Dead-box proteins: a family affair–active and passive players in virus infection. J Exp Med 205: 1523–1527.

29. Cha MY, Ryu DK, Jung HS, Chang HE, Ryu WS (2009) Stimulation of hemorrhagic B Virus genome replication by HBx is linked to both nuclear and cytoplasmic HBx expression. J Gen Virol 90: 978–986.

30. Stack J, Haga IR, Schroder M, Bartellit NW, Maloney G, et al. (2005) Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med 201: 1007–1018.

31. Sells MA, Chen ML, Acs G (1987) Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A 84: 1005–1009.

32. Miyahashi M, Martinez-Sobrido L, Zuo YM, Cardenas WB, Gale M, Jr., et al. (2007) Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol 81: 314–324.

33. Ariumi Y, Kuroki M, Abe K, Dansako H, Ikeda M, et al. (2007) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101–105.

34. Owsianka AM, Patel AH (1999) Hepatitis C virus core protein interacts with a human DEAD box protein DDX3. Virus Res 57: 330–340.

35. Botlagunta M, Vesuna F, Mironchik Y, Ramam A, Lisok A, et al. (2008) Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol 81: 2769–2772.

36. Bowie AG, Unterholzner L (2008) Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 8: 911–922.

37. Isogawa M, Robek MD, Furuichi Y, Chisari FV (2005) Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 79: 2769–2772.

38. Gao H, Jiang D, Ma D, Zhang J, Dougherty AM, et al. (2009) Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J Virol 83: 847–858.

39. Wu J, Lu M, Meng Z, Trippler M, Broering R, et al. (2007) Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 46: 1769–1778.

40. Wang H, Ryu W-S (2009) HBV Polymerase inhibits pattern recognition receptor-mediated innate immune response via its interaction with DDX3 DEAD box RNA helicase. 2009 International meeting The Molecular Biology of Hepatitis B Viruses. pp 169.

41. Yu S, Chen J, Wu M, Chen H, Kato N, et al. (2010) Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKK and RIG-I. J Gen Virol 91: 2080–2090.

42. Ryu DK, Kim S, Ryu WS (2008) Hepatitis B virus polymerase suppresses translation of pregenomic RNA via a mechanism involving its interaction with 5’-stem-loop structure. Virology 373: 112–123.

43. Lee J, Lee HJ, Shin M-K, Ryu W-S (2004) Versatile PCR-mediated insertion or deletion mutagenesis. BioTechniques 36: 398–400.

44. Radzinow G, Tucker W, Schaller H (1990) Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J Virol 64: 613–620.

45. Stack J, Haga IR, Schroder M, Bartellit NW, Maloney G, et al. (2005) Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med 201: 1007–1018.

46. Shin M-K, Lee J, Ryu W-S (2004) A novel cis-acting element facilitates minus-strand DNA synthesis during reverse transcription of the hepatitis B viruses genome. J Virol 78: 6252–6262.

47. Pyronier S, Imataka H, Gissing AG, Fukunaga R, Hunter T, et al. (1999) Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. Embo J 18: 270–279.